Loading...
Asenapine: A Review of Acute and Extension Phase Data in Bipolar Disorder
The second generation atypical antipsychotic, asenapine (Saphris), was approved by the US FDA (August 2009) for the acute treatment of manic or mixed episodes with or without psychotic features associated with bipolar I disorder in adults as well as the acute treatment of schizophrenia. Asenapine ex...
Na minha lista:
| Udgivet i: | CNS Neurosci Ther |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Blackwell Publishing Ltd
2010
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6493886/ https://ncbi.nlm.nih.gov/pubmed/20950326 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1755-5949.2010.00200.x |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|